1. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis
- Author
-
Zilong Yan, Takao Ohtsuka, Yoshinao Oda, Kenoki Ohuchida, Masafumi Nakamura, Shin Takesue, Biao Zheng, Koji Shindo, Makoto Hashizume, Kazuhiro Mizumoto, Yoshihiro Miyasaka, Kohei Nakata, Takashi Okumura, Hiromichi Nakayama, Chika Iwamoto, and Taiki Moriyama
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Kaplan-Meier Estimate ,Metastasis ,Mice ,0302 clinical medicine ,Cell Movement ,RNA, Small Interfering ,Extracellular Signal-Regulated MAP Kinases ,Aged, 80 and over ,Gene knockdown ,Liver Neoplasms ,Cell migration ,General Medicine ,Middle Aged ,Prognosis ,Immunohistochemistry ,Extravasation ,Gene Expression Regulation, Neoplastic ,Oncology ,Gene Knockdown Techniques ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,RNA Interference ,Signal transduction ,Receptors, Thrombopoietin ,Carcinoma, Pancreatic Ductal ,Signal Transduction ,Cell Survival ,Proto-Oncogene Proteins c-myc ,03 medical and health sciences ,Cell Line, Tumor ,Pancreatic cancer ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,Thrombopoietin ,Aged ,business.industry ,medicine.disease ,Xenograft Model Antitumor Assays ,Pancreatic Neoplasms ,Disease Models, Animal ,030104 developmental biology ,Cancer cell ,Cancer research ,business - Abstract
This study aimed at investigating the function and significance of CD110 expression in pancreatic cancer. We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer. We evaluated clinical outcomes and other clinicopathological factors to determine the significance of CD110 on survival and liver metastasis. We examine thrombopoietin–CD110 signaling in cancer cell extravasation in vitro and in vivo. We investigated the effects of CD110 knockdown on liver metastasis in a splenic xenograft mouse model. CD110 expression in cancer cells was associated with low-histological-grade invasive ductal carcinoma, and patients with high CD110 expression had poorer prognosis (P = 0.0003). High CD110 expression was an independent predictor of liver metastasis (P = 0.0422). Knockdown of CD110 expression significantly attenuated cell migration and invasion. Treatment with thrombopoietin promoted pancreatic cancer cell extravasation. In the presence of thrombopoietin, CD110 increased cell viability through the activation of the ERK–MYC signaling pathway. Knockdown of CD110 expression inhibited liver metastases in the mouse model. CD110 promotes pancreatic cancer progression and it may serve as a predictive factor for liver metastasis.
- Published
- 2019
- Full Text
- View/download PDF